Evaluation of therapeutic effect of intracordal bFGF administration on vocal fold atrophy (including presbylarynx), sulcus vocalis

eha Rumi0 个研究点目标入组 33 人开始时间: 2023年3月3日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Patients aged 18 years or older (regardless of gender)
•(2) Patient diagnosed with vocal fold atrophy (including presbylarynx) or sulcus vocalis as a voice disorder
•(3) Patients who wish to improve voice impairment due to vocal fold atrophy (including presbylarynx) or sulcus vocalis
•(4) Patients who have been fully informed about their participation in this study, and who have given written consent of their own free will based on a thorough understanding of the study

•(1) Patients with obvious tumors on the vocal cords
•(2) Patients with malignant tumors anywhere in the body (cancer-bearing condition)
•(3) Patients with a history of malignant tumors on the vocal cords
•(4) Patients with a history of severe drug allergies or side effects
•(5) Patients with a history of hypersensitivity to trafermin (genetical recombination)
•(6) Pregnant, lactating, or possibly pregnant patients
•(7) Patients who are judged inappropriate for participation in this study by the principal investigator or co-investigator

发起方

eha Rumi